Orchard Therapeutics plc American Depositary Shares
ORTX
ORTX was delisted on the 23rd of January, 2024.
43 hedge funds and large institutions have $875M invested in Orchard Therapeutics plc American Depositary Shares in 2019 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 9 increasing their positions, 12 reducing their positions, and 5 closing their positions.
120% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 5
16% more funds holding
Funds holding: 37 → 43 (+6)
14% more capital invested
Capital invested by funds: $765M → $875M (+$110M)
0.25% more ownership
Funds ownership: 38.75% → 39.01% (+0.25%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
25% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
+$7.86M |
| 2 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$5.73M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$4.14M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$3.94M |
| 5 |
EU
Emory University
Atlanta,
Georgia
|
+$2.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$10.5M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$4.96M |
| 3 |
VMI
VHCP Management III
New York
|
-$3.46M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.59M |
| 5 |
VMI
VHCP Management II
New York
|
-$2.05M |
ORTX Hedge Fund Activity: Q1 2019 in Review
43 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Orchard Therapeutics plc American Depositary Shares (ORTX) for Q1 2019, worth a combined $875M — up 14% from $765M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ORTX positions and 5 closed out — a net gain of 6 holders — while 9 added to existing stakes and 12 trimmed.
The largest buyer was Westfield Capital Management, opening a new position worth an estimated $7.86M. The largest seller was Foresite Capital Management IV, exiting entirely with an estimated $10.5M sold.
- 43 institutional investors held Orchard Therapeutics plc American Depositary Shares (ORTX) as of Q1 2019, up from 37 in Q4 2018.
- Funds reported $875M of Orchard Therapeutics plc American Depositary Shares stock for Q1 2019, up 14% quarter-over-quarter.
- 11 funds opened new Orchard Therapeutics plc American Depositary Shares positions in Q1 2019 and 5 closed out, a net change of +6 holders.
- The largest Orchard Therapeutics plc American Depositary Shares buyer in Q1 2019 was Westfield Capital Management, an estimated $7.86M added.
- The largest Orchard Therapeutics plc American Depositary Shares seller in Q1 2019 was Foresite Capital Management IV, an estimated $10.5M sold.
Based on aggregated 13F filings for Q1 2019.